Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug666 | Blood test for IgG antibodies against SARS-CoV-2 Wiki | 0.71 |
drug3195 | Placebo Wiki | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
D001049 | Apnea NIH | 0.41 |
D012891 | Sleep Apnea, NIH | 0.29 |
D020181 | Sleep Apnea, Obstructive NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002104 | Apnea HPO | 0.41 |
HP:0002870 | Obstructive sleep apnea HPO | 0.29 |
HP:0010535 | Sleep apnea HPO | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006536 | Pulmonary obstruction HPO | 0.17 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.16 |
HP:0002088 | Abnormal lung morphology HPO | 0.12 |
Navigate: Correlations HPO
There are 2 clinical trials
The primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65 years; elderly >=65 to 90 years) with moderate to severe obstructive sleep apnea (OSA) compared with placebo, and using pulse oximetry determine whether lemborexant decreases the peripheral oxygen saturation (SpO2) during total sleep time (TST) on Day 8 of treatment in adult and elderly participants (adults >=45 to <65 years; elderly >=65 to 90 years) with moderate to severe chronic obstructive pulmonary disease (COPD) compared with placebo.
Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using polysomnography (PSG). The International Classification of Sleep Disorders (ICSD) (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: OSA Cohort: AHI on Day 8 of Treatment Time: Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: COPD Cohort: Mean SpO2 During TST on Day 8 of Treatment Time: Day 8Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using PSG. The ICSD (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: AHI on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1; COPD Cohort: Day 1 and Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Mean SpO2 During TST on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1 and Day 8; COPD Cohort: Day 1Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Percentage of TST During Which the SpO2 is <90 percent (%), <85% and <80% on Day 1 and Day 8 of Treatment Time: Day 1 and Day 8Description: ODI is defined as (oxygen desaturations >=3%*60)/TST (that is, the average number of oxygen desaturations >=3% per hour of sleep), as defined by the American Academy of Sleep Medicine. ODI will be assessed using PSG.
Measure: Mean Oxygen Desaturation Index (ODI) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Description: Desaturation is defined as decrease in the mean SpO2 of >=3% (over the last 120 seconds) that lasts for at least 10 seconds. Desaturation will be assessed using PSG.
Measure: Absolute Number of Desaturations (>=3% Reduction From Baseline SpO2) on Days 1 and 8 of Treatment Time: Day 1 and Day 8The primary purpose of the study is to determine whether lemborexant increases the apnea hypopnea index (AHI) on Day 8 of treatment in adult and elderly participants (adults greater than or equal to [>=] 45 to less than [<] 65 years; elderly >=65 to 90 years) with moderate to severe obstructive sleep apnea (OSA) compared with placebo, and using pulse oximetry determine whether lemborexant decreases the peripheral oxygen saturation (SpO2) during total sleep time (TST) on Day 8 of treatment in adult and elderly participants (adults >=45 to <65 years; elderly >=65 to 90 years) with moderate to severe chronic obstructive pulmonary disease (COPD) compared with placebo.
Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using polysomnography (PSG). The International Classification of Sleep Disorders (ICSD) (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: OSA Cohort: AHI on Day 8 of Treatment Time: Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: COPD Cohort: Mean SpO2 During TST on Day 8 of Treatment Time: Day 8Description: AHI is defined as the average number of apneas and hypopneas per hour of sleep. AHI will be assessed using PSG. The ICSD (American Academy of Sleep Medicine, 2014) defines the severity of OSA according to the AHI: an AHI >5 to <15 is classed as mild, AHI >=15 to <30 as moderate, and AHI >=30 as severe.
Measure: AHI on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1; COPD Cohort: Day 1 and Day 8Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Mean SpO2 During TST on Day 1 and Day 8 of Treatment Time: OSA Cohort: Day 1 and Day 8; COPD Cohort: Day 1Description: SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 is monitored by noninvasive method known as transmissive pulse oximetry. TST is defined as the total time asleep in minutes using PSG.
Measure: Percentage of TST During Which the SpO2 is <90 percent (%), <85% and <80% on Day 1 and Day 8 of Treatment Time: Day 1 and Day 8Description: ODI is defined as (oxygen desaturations >=3%*60)/TST (that is, the average number of oxygen desaturations >=3% per hour of sleep), as defined by the American Academy of Sleep Medicine. ODI will be assessed using PSG.
Measure: Mean Oxygen Desaturation Index (ODI) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Description: Desaturation is defined as decrease in the mean SpO2 of >=3% (over the last 120 seconds) that lasts for at least 10 seconds. Desaturation will be assessed using PSG.
Measure: Absolute Number of Desaturations (>=3% Reduction From Baseline SpO2) on Days 1 and 8 of Treatment Time: Day 1 and Day 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports